Ribavirin for COVID-19

Home

Ribavirin has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.

ribavirin Submit Updates

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Celik et al., In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase, Molecular Diversity, doi:10.1007/s11030-021-10215-5

Kapoor et al., In silico evaluation of potential intervention against SARS-CoV-2 RNA-dependent RNA polymerase, Physics and Chemistry of the Earth, Parts A/B/C, doi:10.1016/j.pce.2022.103350

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Wang et al., Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization, Frontiers in Genetics, doi:10.3389/fgene.2021.749256

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit